local_hospital

Somni bene Institut fuer medizinische Forschung und Schlafmedizin Schwerin GmbH

Address
lock Available on a paid plan

Sleep Medicine and Circadian Disorders

At Somni bene Institut fuer medizinische Forschung und Schlafmedizin Schwerin GmbH, a major focus is on sleep medicine and circadian rhythm disorders. Research here includes insomnia disorder, delayed sleep-wake phase disorder, narcolepsy with cataplexy, and sleep problems linked to nocturia and menopause, with studies aimed at improving symptom control and daily functioning.

  • Evaluating new treatments for insomnia and related sleep disruption
  • Studying therapies for circadian rhythm misalignment and sleep timing problems
  • Assessing options for narcolepsy and excessive daytime sleepiness

This work is centered on finding safer and more effective ways to improve sleep quality, restore regular sleep patterns, and reduce the impact of sleep-related conditions on everyday life.

Pain, Neurology, and Musculoskeletal Research

The site also conducts trials in nervous system diseases and musculoskeletal diseases, especially for people living with diabetic peripheral neuropathic pain, chronic low back pain, and other persistent pain conditions. These studies are designed to test new approaches that may better relieve pain when standard treatments are not enough.

  • Testing treatments for diabetic neuropathic pain
  • Exploring options for chronic non-specific low back pain
  • Evaluating pain relief strategies for difficult-to-treat chronic pain

The research reflects a strong interest in improving pain management, especially for patients whose symptoms remain uncontrolled despite usual care.

Psychiatry and Mood Disorders

A substantial part of the clinical research portfolio addresses psychiatry and psychology, particularly major depressive disorder and depression with anxious distress. Trials in this area are focused on assessing new antidepressant strategies and adjunctive treatments to support people who do not respond adequately to existing therapy.

  • Investigating treatments for major depressive disorder
  • Studying add-on approaches for inadequate antidepressant response
  • Examining safety and symptom improvement in depression with anxious distress

These studies aim to improve mood symptoms, expand treatment choices, and offer more personalized options for adults living with depression.

Metabolic Health and Obesity-Related Conditions

Research at the Schwerin site also covers nutritional and metabolic diseases, including obesity and overweight. Some trials connect metabolic health with breathing and sleep outcomes, reflecting the close relationship between body weight, sleep quality, and overall health.

  • Evaluating therapies for obesity and overweight
  • Studying the impact of weight-related treatment on obstructive sleep apnea
  • Exploring links between metabolic health and sleep-related disease burden

The goal is to identify treatments that may support healthier weight management while also improving related symptoms such as breathing disturbances during sleep.

Women’s Health and Sleep-Related Symptoms

The site includes research in female urogenital diseases and pregnancy complications, with attention to symptoms that affect women’s wellbeing, such as sleep disturbances associated with menopause. This area links women’s health to restorative sleep and quality of life.

  • Studying sleep disruption linked to menopause
  • Assessing symptom relief in women with hormone-related sleep problems
  • Exploring new approaches to improve night-time rest and daytime comfort

These trials are intended to better understand how women’s health conditions affect sleep and to evaluate therapies that may ease these burdens.

Cross-Disciplinary Symptom Management

Several studies at Somni bene Institut fuer medizinische Forschung und Schlafmedizin Schwerin GmbH bridge multiple therapeutic areas, combining sleep medicine, pain research, psychiatry, and metabolic health. This reflects a broader effort to address symptoms that often overlap across conditions, such as fatigue, poor sleep, pain, and reduced wellbeing.

  • Testing therapies that target more than one symptom domain
  • Evaluating treatment effectiveness in complex, overlapping conditions
  • Improving quality of life through better symptom control

The research landscape is broad but connected, with a clear emphasis on practical treatments that may help patients manage chronic conditions more effectively.

Site Overview

assignment
18
connected trials
corporate_fare
14
sponsors
science
20
IMPs

Activity Indicator

Last 6 months

3
Trials started
+200% vs previous period.
1
Trials started 6–12 months ago
18
Total trials linked
Highly Active
trending_upGrowing+200%
1
2
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 therapeutic areas and 15 of 20 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
6
Sponsors (total)
14
Active sponsors
4

Sponsor Network

Top 4 by active trials.

lock +3 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +4 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 2 161 other sites in Germany

description
Trial volume
18
Outperforms 89% of sites
public
Therapeutic diversity
5areas
Outperforms 89% of sites
groups
Sponsor diversity
14sponsors
Outperforms 91% of sites

Therapeutic Area Benchmark — Germany

Select a therapeutic area to compare against other sites in Germany.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Germany

Market Share

Country: Germany

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Somni bene Institut fuer medizinische Forschung und Schlafmedizin Schwerin GmbH

lock Showing 1 of 18 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A multi-center, double-blind, randomized, placebo-controlled, 2-way cross-over post approval study to investigate the efficacy of daridorexant in subjects with insomnia and comorbid nocturiaIdorsia Pharmaceuticals Ltd.Phase IIINot RecruitingMar 2023Apr 2024

IMP list

lock Showing 1 of 20 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Alks 26802Unknown

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.